Author: Abhishek Gulati

Adaptive PD-optimal design of a pilot study for a clotting time test for enoxaparin

Abhishek Gulati (1), James M Faed (2), Geoffrey K Isbister (3,4), Stephen B Duffull (1)
School of Pharmacy, University of Otago, Dunedin, New Zealand, Department of Pathology, School of Medicine, University of Otago, Dunedin, New Zealand, Department of Clinical Toxicology and Pharmacology, Calvary Mater Hospital, NSW, Australia, Discipline of Clinical Pharmacology, University of Newcastle, NSW, Australia

Background: Dosing of enoxaparin, like other anticoagulants, may result in bleeding following excessive doses and clot formation if the dose is too low. There is no standard measure of enoxaparin clinical effectiveness. We recently showed that a Xa clotting time test could potentially assess the effect of enoxaparin on the clotting system [1]. Preliminary in […]

Read More

Identification and initial evaluation of a prototype clotting time test for enoxaparin

Abhishek Gulati (1), James M Faed (2), Geoffrey K Isbister (3,4), Stephen B Duffull (1)
(1) School of Pharmacy, University of Otago, Dunedin, New Zealand, (2) Department of Pathology, School of Medicine, University of Otago, Dunedin, New Zealand, (3) Department of Clinical Toxicology and Pharmacology, Calvary Mater Hospital, NSW, Australia, (4) Discipline of Clinical Pharmacology, University of Newcastle, NSW, Australia

Background: Enoxaparin is a low molecular weight heparin anticoagulant and is widely used in thromboprophylaxis for both prevention of primary thrombosis and at higher doses for treatment in patients with pulmonary embolism, deep vein thrombosis and acute coronary syndromes. Dosing of enoxaparin, like other anticoagulants, may result in bleeding following excessive doses and clot formation if […]

Read More